Telehealth & Digital Health

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

A landmark study confirms a minimally invasive radiofrequency device is highly effective for chronic rhinitis, offering lasting relief beyond traditional sprays.

With new backing from One Six 8 Ventures, health tech firm Respiree accelerates its US and Canadian expansion of its FDA-cleared AI platform.

Dupixent's landmark FDA approval offers a new, surgery-sparing option for a debilitating sinus disease, but questions of access and cost remain.

A new report shows most medical practices are flying blind, with only 7% confident in tracking revenue, leading to massive, preventable financial losses.

Despite missing its primary goal, Cadrenal Therapeutics' drug CAD-1005 drastically cut deadly blood clots, setting up a crucial FDA meeting for a new path forward.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.

After an 8-year hiatus, Elizabeth Arden launches Eternal Aura. A look at the strategy combining a new star, wellness science, and heritage to reclaim its spot.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

After gaining FDA alignment, INmune Bio is advancing its inflammation-targeting drug, XPro1595, offering a novel and potentially safer approach for patients.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

Teva and Medincell’s once-monthly olanzapine injection shows promise in trials, potentially freeing patients from burdensome post-injection observation.

New research reveals how clinical trial design inflates the placebo effect, offering a key to solving the 90% failure rate for anxiety and depression drugs.

MAIA Pharmaceuticals will bring Teribone™, a proven therapy used in Japan, to the US, aiming to solve the critical patient adherence crisis in osteoporosis care.

The Hume Band challenges rivals with a no-subscription model and longevity tracking, but user complaints and questions about its tech cloud its bold promises.

A new digital health partnership embeds AI coaching into a wellness app, promising 24/7 support for mental health and chronic conditions at scale.

A new partnership model merges virtual nephrology, clinical trials, and real-world data, aiming to empower independent doctors and improve patient access.

The spatial biology leader will unveil its roadmap at AGBT 2026, targeting the next frontiers of drug discovery with 3D imaging and human-relevant models.